Predictors of sustained response to alpha interferon therapy in chronic hepatitis C

被引:90
作者
Martinot-Peignoux, M
Boyer, N
Pouteau, M
Castelnau, C
Giuily, N
Duchatelle, V
Aupérin, A
Degott, C
Benhamou, JP
Erlinger, S
Marcellin, P [1 ]
机构
[1] Hop Beaujon, INSERM, U481, Serv Hepatol, F-92118 Clichy, France
[2] Hop Beaujon, Ctr Rech Claude Bernard Hepatites Virales, Clichy, France
[3] Hop Beaujon, Serv Anat & Cytol Pathol, Clichy, France
关键词
chronic hepatitis C; HCV genotype; IFN therapy; predictive factors; serum HCV RNA; sustained response;
D O I
10.1016/S0168-8278(98)80006-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The aim of this study was to determine the predictors for sustained response to alpha interferon therapy in a large population of patients,vith chronic hepatitis C, using multivariate analysis. Methods: Two hundred and ninety-six patients were included in four controlled trials of alpha interferon. Pretreatment serum HCV RNA levels mere assessed by the branched DNA version 2.0 assay and HCV genotypes by the reverse hybridization assay (LiPA). Results: Sustained responses were observed in 37%, 14% and 6% of the patients with low, medium and high pretreatment serum HCV RNA levels, respectively (p<10(-4)). Sustained responses were observed in 5%, 4%, 32% and 27% of the patients with genotype 1a, 1b, 2a and 3a, respectively (p<10(-4)). The multivariate analysis showed that a non-transfusional source of HCV infection, low serum HCV RNA levels and HCV genotypes non-1 (2a or 3a) were independent factors associated with sustained response to interferon therapy. Conclusion: Virological factors (low pretreatment serum HCV RNA level and HCV genotype non-1a and non-1b), when adjusted in a large population of patients, using improved technology, are the main independent predictors of sustained response to alpha interferon therapy.
引用
收藏
页码:214 / 223
页数:10
相关论文
共 34 条
  • [1] BACON BR, 1995, HEPATOLOGY, V22, P37
  • [2] BENHAMOU JP, 1995, HEPATOLOGY, V22, P37
  • [3] COMPARISON OF 1 OR 3 MU OF INTERFERON ALFA-2B AND PLACEBO IN PATIENTS WITH CHRONIC NON-A, NON-B HEPATITIS
    CAUSSE, X
    GODINOT, H
    CHEVALLIER, M
    CHOSSEGROS, P
    ZOULIM, F
    OUZAN, D
    HEYRAUD, JP
    FONTANGES, T
    ALBRECHT, J
    MESCHIEVITZ, C
    TREPO, C
    [J]. GASTROENTEROLOGY, 1991, 101 (02) : 497 - 502
  • [4] CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4
  • [5] CONJEEVARAM HS, 1995, HEPATOLOGY, V22, P1326, DOI 10.1002/hep.1840220444
  • [6] DAVIS G, 1997, HEPATOLOGY S, V20, P123
  • [7] DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603
  • [8] TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL
    DAVIS, GL
    BALART, LA
    SCHIFF, ER
    LINDSAY, K
    BODENHEIMER, HC
    PERRILLO, RP
    CAREY, W
    JACOBSON, IM
    PAYNE, J
    DIENSTAG, JL
    VANTHIEL, DH
    TAMBURRO, C
    LEFKOWITCH, J
    ALBRECHT, J
    MESCHIEVITZ, C
    ORTEGO, TJ
    GIBAS, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) : 1501 - 1506
  • [9] RECOMBINANT INTERFERON-ALFA THERAPY FOR CHRONIC HEPATITIS-C - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    DIBISCEGLIE, AM
    MARTIN, P
    KASSIANIDES, C
    LISKERMELMAN, M
    MURRAY, L
    WAGGONER, J
    GOODMAN, Z
    BANKS, SM
    HOOFNAGLE, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) : 1506 - 1510
  • [10] The treatment of chronic viral hepatitis
    Hoofnagle, JH
    DiBisceglie, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (05) : 347 - 356